Novo Nordisk A/S (NYSE:NVO) Shares Down 2.5% – Here’s What Happened

Novo Nordisk A/S (NYSE:NVO)’s stock price was down 2.5% on Wednesday . The stock traded as low as $37.00 and last traded at $37.4760. Approximately 25,317,597 shares were traded during mid-day trading, an increase of 1% from the average daily volume of 25,111,252 shares. The stock had previously closed at $38.43.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Sanford C. Bernstein initiated coverage at “outperform” with a $175 price target — a very bullish stamp that can attract buyers and support shares despite recent weakness.
• Positive Sentiment: A new study found stopping GLP‑1 therapy raises risks of heart attack, stroke and death in Type 2 diabetes patients, reinforcing the clinical value and stickiness of GLP‑1 drugs like semaglutide (Wegovy/Ozempic), which supports long‑term demand. Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
• Positive Sentiment: Partnerships expanding access (e.g., Hims & Hers distribution of GLP‑1s) could broaden patient reach and support steady volume growth for Novo’s obesity/diabetes portfolio. Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know
• Neutral Sentiment: Commentary pieces are debating whether the recent price decline makes NVO a value buy; that keeps investor attention high but creates mixed flows as value and momentum investors disagree. Is Novo Nordisk (NYSE:NVO) Starting To Look Interesting After A 52% One Year Slide?
• Negative Sentiment: New clinical data from a rival oral GLP‑1 (aleniglipron) showed weight‑loss results comparable to Wegovy, increasing competitive pressure in obesity — a direct threat to pricing and market share. Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
• Negative Sentiment: Reports say Novo Nordisk stands to lose key semaglutide patent protection in India soon, opening the door to low‑cost generics in a large, price‑sensitive market — a risk to long‑term sales and margin assumptions. Novo Nordisk Patent Loss In India Tests GLP 1 Valuation Story
• Negative Sentiment: The Portnoy Law Firm has opened an investigation into possible securities fraud involving Novo Nordisk, a headline that can prompt selling pressure and increase short‑term volatility. Novo Nordisk A/S Investigated by the Portnoy Law Firm

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NVO. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price objective for the company. in a research report on Tuesday, March 10th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. CICC Research assumed coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. Finally, Citigroup began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating for the company. Four equities research analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Performance

The company has a fifty day moving average price of $49.45 and a two-hundred day moving average price of $51.48. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company has a market capitalization of $167.33 billion, a P/E ratio of 10.80 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is 52.74%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NVO. True Wealth Design LLC increased its stake in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares during the period. Guerra Advisors Inc acquired a new position in shares of Novo Nordisk A/S in the third quarter worth approximately $25,000. Godfrey Financial Associates Inc. bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $25,000. WealthCollab LLC boosted its holdings in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the last quarter. Finally, American National Bank & Trust acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at approximately $28,000. 11.54% of the stock is owned by institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.